Torsten M. Madsen Net Worth

The estimated Net Worth of Torsten M. Madsen is at least $14.2 Mille dollars as of 28 January 2019. Torsten Madsen owns over 1,050 units of Aptinyx Inc stock worth over $14,189 and over the last 6 years Torsten sold APTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Torsten Madsen APTX stock SEC Form 4 insiders trading

Torsten has made over 2 trades of the Aptinyx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Torsten bought 1,050 units of APTX stock worth $5,534 on 28 January 2019.

The largest trade Torsten's ever made was buying 1,050 units of Aptinyx Inc stock on 28 January 2019 worth over $5,534. On average, Torsten trades about 683 units every 72 days since 2018. As of 28 January 2019 Torsten still owns at least 232,600 units of Aptinyx Inc stock.

You can see the complete history of Torsten Madsen stock trades at the bottom of the page.

What's Torsten Madsen's mailing address?

Torsten's mailing address filed with the SEC is C/O APTINYX INC., 909 DAVIS STREET, SUITE 600, EVANSTON, IL, 60201.

Insiders trading at Aptinyx Inc

Over the last 6 years, insiders at Aptinyx Inc have traded over $0 worth of Aptinyx Inc stock and bought 10,337,357 units worth $55,328,087 . The most active insiders traders include Street Partners Llc Adams, Patrick G Enright e James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of $18,161. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth $50,091.

What does Aptinyx Inc do?

welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.

Complete history of Torsten Madsen stock trades at Aptinyx Inc

Aptinyx Inc executives and stock owners

Aptinyx Inc executives and other stock owners filed with the SEC include:

• Norbert Riedel,
  President, Chief Executive Officer, Director
• Ashish Khanna,
  Chief Financial Officer, Chief Business Officer
• Andrew Kidd,
  Chief Operating Officer
• Dr. Norbert G. Riedel,
  Exec. Chairman
• Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
  CEO, Pres & Director
• Ashish Khanna,
  CFO & Chief Bus. Officer
• Henry Gosebruch,
  Independent Director
• Rachel Sherman,
  Independent Director
• Robert Hombach,
  Independent Director
• Patrick Enright,
  Independent Chairman of the Board
• Adam Koppel,
  Independent Director
• Elisha Gould,
  Independent Director
• Tim Noffke,
  VP of Program Management & Chief of Staff
• Dr. Harald Murck M.D., Ph.D.,
  VP of Clinical & Medical Affairs
• Patrick Flavin,
  Sr. Mang. of Corp. Devel. & Investor Relations
• Dr. Kathryn King Ph.D.,
  Sr. VP of Clinical & CMC Operations
• Molly Dir,
  VP of HR
• Juan Estupinan,
  VP of Fin. & Accounting and Controller
• Capital Life Sciences Inves...,
  
• Gilmore Neil O'neill,
  
• Terry P Gould,
  
• Leaf Venture Management Iii...,
  
• David Houck,
  Chief Development Officer
• Torsten M. Madsen,
  Chief Medical Officer
• James N Topper,
  Director
• Life Sciences Viii, L.P.Fhm...,
  
• Capital Partners Ii, Llc Ta...,
  
• Wilbur H Gantz,
  Director
• Joseph R. Moskal,
  Chief Scientific Officer
• Street Partners Llc Adams,
  10% owner
• Liam Ratcliffe,
  Director
• Joan W. Miller,